| First Author | Kameyama H | Year | 2023 |
| Journal | Cell Rep Med | Volume | 4 |
| Issue | 12 | Pages | 101330 |
| PubMed ID | 38118415 | Mgi Jnum | J:352700 |
| Mgi Id | MGI:7663321 | Doi | 10.1016/j.xcrm.2023.101330 |
| Citation | Kameyama H, et al. (2023) Needle biopsy accelerates pro-metastatic changes and systemic dissemination in breast cancer: Implications for mortality by surgery delay. Cell Rep Med 4(12):101330 |
| abstractText | Increased breast cancer (BC) mortality risk posed by delayed surgical resection of tumor after diagnosis is a growing concern, yet the underlying mechanisms remain unknown. Our cohort analyses of early-stage BC patients reveal the emergence of a significantly rising mortality risk when the biopsy-to-surgery interval was extended beyond 53 days. Additionally, histology of post-biopsy tumors shows prolonged retention of a metastasis-permissive wound stroma dominated by M2-like macrophages capable of promoting cancer cell epithelial-to-mesenchymal transition and angiogenesis. We show that needle biopsy promotes systemic dissemination of cancer cells through a mechanism of sustained activation of the COX-2/PGE(2)/EP2 feedforward loop, which favors M2 polarization and its associated pro-metastatic changes but are abrogated by oral treatment with COX-2 or EP2 inhibitors in estrogen-receptor-positive (ER(+)) syngeneic mouse tumor models. Therefore, we conclude that needle biopsy of ER(+) BC provokes progressive pro-metastatic changes, which may explain the mortality risk posed by surgery delay after diagnosis. |
